ArticleCancers2026

TGFB2 as a Prognostic Biomarker Associated with Myeloid-Enriched, Multi-Checkpoint-Activated Immunosuppression in Diffuse Glioma: A Multi-Cohort Transcriptomic Study.

Ehab Balawi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.